
CLAIMS

1. Use of a VAP-1 inhibitor in the manufacture of a medicament for the prevention and/or treatment of migraine, wherein the VAP-1 inhibitor is a compound of Formula (III) or a pharmaceutically acceptable salt, or N-oxide thereof:



(III),

wherein:

R^1 is a phenyl ring or a 5- or 6-membered heteroaryl ring, either ring being optionally substituted with one or more substituents selected from halogen, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, a 3-7 membered cycloalkyl ring, $-OR^5$, $-NR^{4A}R^{4B}$, $-NR^6C(O)OR^5$, $-NR^6C(O)R^5$, $-NR^6C(O)NR^{4A}R^{4B}$, $-C(O)NR^{4A}R^{4B}$, $-C(O)R^5$, $-C(O)OR^5$, and $-NR^6S(O)_2R^5$;


R^{4A}, R^{4B}, R^5, and R^6 are each independently selected from hydrogen, C_{1-4}-alkyl, and halo-C_{1-4}-alkyl, or

R^{4A} and R^{4B} together with the nitrogen to which they are attached form a 3-7 membered cyclic amino group, optionally substituted by one or more substituents selected from halogen, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, C_{1-4}-alkoxy, halo-C_{1-4}-alkoxy, $-CONH_2$, $-SO_2NH_2$, $-NH_2$, $-NHC_{1-4}$-alkyl, and -NHhalo-C_{1-4}-alkyl; and

R^3 is a 3-7 membered heterocyclic ring, a 3-7 membered cycloalkyl ring, or a 5- or 6-membered heteroaryl ring, any one of the rings being optionally substituted with one or more substituents selected from halogen, oxo, hydroxyl, cyano, C_{1-4}-alkyl, halo-C_{1-4}-alkyl, cyano-C_{1-4}-alkyl, $-OR^5$, $-NR^{4A}R^{4B}$, $-NR^6C(O)OR^5$, $-NR^6C(O)R^5$, $-NR^6C(O)NR^{4A}R^{4B}$, $-C(O)NR^{4A}R^{4B}$, $-C(O)R^5$, $-C(O)OR^5$, $-SO_2R^5$, $-SO_2NR^{4A}R^{4B}$, and $-NR^6S(O)_2R^5$.

2. The use according to claim 1, wherein R^1 is a phenyl ring optionally substituted with one or more substituents as defined in claim 1.

3. The use according to claim 1 or 2, wherein the VAP-1 inhibitor is a compound of Formula (IIIa) or a pharmaceutically acceptable salt, or N-oxide thereof.



(IIIa)

.

4. The use according to any one of claims 1 and 3, wherein R^3 is a 3-7 membered heterocyclic ring optionally substituted with one or more substituents as defined in claim 1.

5. The use according to any one of claims 1 to 4, wherein R^3 is a piperazine or morpholine ring optionally substituted with one or more substituents as defined in claim 1.

6. The use according to claim 5, wherein the piperazine or morpholine ring of R^3 is joined to the rest of the molecule through a nitrogen atom of that piperazine or morpholine ring.

7. The use according to any one of claims 1 to 6, wherein R^3 is a piperazine ring substituted with at least one substituent as defined in claim 1 on a nitrogen atom in that piperazine ring.

8. The use according to any one of claims 1 to 6, wherein the VAP-1 inhibitor is selected from the group consisting of




1-(4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}piperazin-1-yl)ethan-1-one;


4-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}morpholine; and

1-{5-[3-(4-Fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl]pyridin-2-yl}-4-methanesulfonylpiperazine.


9. The use according to any one of claims 1, 2, and 4 to 7, wherein R^1 is phenyl or pyridyl, optionally substituted with one or more substituents selected from F, Cl, and CH_3.


10. The use according to any one of claims 1 to 7, and 9, wherein R^3 is selected from the group consisting of:



,

,

,



,

,


,


,
and


, and


wherein R^8 is selected from hydrogen, CH_3, -$CONH_2$, -$NHCONH_2$, -$S(O)_2CH_3$, and -$COCH_3$.

11. The use according to any preceding claim, wherein migraine is selected from the group consisting of headache, chronic migraine, episodic migraine, medication overuse headache disorder (MOU), migraine without aura, migraine with aura, migraine aura without headache, ocular migraine, vestibular migraine, basilar migraine, hemiplegic migraine, ophthalmoplegic migraine, and tension-type headache (TTH).

12. The use according to claim 11, wherein migraine is medication overuse headache disorder (MOU).


13. The use according to any preceding claim, wherein the use is for the prevention of migraine.

14. The VAP-1 inhibitor for use according to any preceding claim, wherein R^1 is:



.

15. The VAP-1 inhibitor for use according to any preceding claim, wherein R^3 is:




,

wherein R^8 is selected from hydrogen, CH_3, -$CONH_2$, -$NHCONH_2$, -$S(O)_2CH_3$, and -$COCH_3$.

16. The VAP-1 inhibitor for use according to claim 6, wherein R^8 is -$COCH_3$.


17. The VAP-1 inhibitor for use according to claim 6, wherein R^8 is -$S(O)_2CH_3$.

18. The VAP-1 inhibitor for use according to any preceding claim, wherein R^3 is:




.

19. The VAP-1 inhibitor for use according to any preceding claim, wherein the VAP-1 inhibitor is:




.

20. The VAP-1 inhibitor for use according to any preceding claim, wherein the VAP-1 inhibitor is:



.

21. The VAP-1 inhibitor for use according to any preceding claim, wherein the VAP-1 inhibitor is:



.